Wednesday, June 11, 2014

Hybrid aspirin can be a new, safer treatment for mesothelioma

Mesothelioma is an aggressive, incurable form of cancer primarily caused by asbestos exposure to air. Close to 3,000 American cancer diagnosed each year with veterans, accounting for almost 30 percent of all cases. While there is no cure for mesothelioma, the symptoms can be treated with varying degrees of success through surgery, chemotherapy and radiation.

Mesothelioma patients rarely hear "Take two aspirin and call me in the morning" in the fight against the rare cancer. But researchers the City College of New York reports that she have a new hybrid aspirin have developed, which can be the latest potent cancer fighter. So aspirin, to treat frequently in the future might mesothelioma if, the results of the study.

In a study, published in the journal of ACS medicinal chemistry letters, scientists report that they have developed a new aspirin compound, which kept the growth of 11 different types of human cancer cells in culture in the bridle. Some of the cancers in lab contain controlled pancreatic, lung and leukemia.

"If what we have seen, can be translated in animals to humans", said Associate Professor Khosrow Kashfi, the principal investigator "it [the aspirin] could in conjunction with other drugs be used to shrink tumors before chemotherapy or surgery."

Chemotherapy, which often is the primary modality for the treatment of patients with mesothelioma, is notorious for its side effects, including low blood cells, dilution or brittle hair, loss of appetite and weight loss, diarrhea, nausea and vomiting. This new aspirin but which was found maybe safer than the current standard aspirin and could the dosage of chemotherapy, which limit required for the supply.

"There is a lot of data on aspirin, which show that periodically hit, average it reduces the risk of developing colon cancer by about 50% compared to non-users," said 1958–2008.

The downside, however, is that prolonged use of aspirin is associated with bleeding, ulcers and other serious diseases due to its toxicity.

Named "NOSH" aspirin, is developed the drug, a combination of nitric oxide (no), helps protect of the stomach lining and hydrogen sulphide (H2S) by researchers of the City College, has been proven, that enhance aspirin-cancer-fighting ability.

"The most important components of this new connection are that it is very, very strong and yet it has minimal toxicity to the cells," said 1958–2008.

The researchers found that the NOSH-aspirin treatment showed promise in tumors shrink and slows cancer growth. In fact, the compound has been shrinking human colon cancer tumors to animals living in 85 percent without side effects.

The researchers admit NOSH aspirin use is still years away and there must be clinical studies and toxicity before approval to undergo tests.

For the 3,000 Americans diagnosed each year with mesothelioma clinical trials are crucial for the patient offers the possibility new, potentially more effective therapies, get.  If this new treatment to successfully prove to humans than mice continue, the breakthrough could be it, all mesothelioma patients and their doctors already expected.

Hybrid aspirin can be a new, safer treatment for mesothelioma

No comments:

Post a Comment